http://www.delmarpharma.com/ Del Mar Pharma is developing new drug candidates targeting orphan cancer indications representing market opportunities in the US$100s of millions in North America and potentially billions of dollars worldwide. We aim to develop products that will have a high impact in patient care and a high return for our investors. In order to accelerate our development timelines and reduce technical risk, we leverage existing clinical and commercial data from a wide range of sources. This business model has been well validated and demonstrated to position for investor exit with significant upside, even prior to commercialization.
Key elements of our business strategy include:
Del Mar Pharma's first product candidate, VAL-083, benefits from an historical investment of more than US$50 million by the National Cancer Institute (NCI) in the United States. The drug is well-characterized and has been studied in more than 40 Phase I & Phase II NCI-sponsored human clinical trials in the United States and in Europe. VAL-083 is approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia and solid tumors, including lung cancer.